CRISPR Libraries

New libraries. New capabilities. New discoveries.

Thermo Fisher Scientific is applying the power of the CRISPR-Cas9 system to high throughput screening applications with our new awarding winning pooled and arrayed CRISPR libraries. These CRISPR libraries are designed to provide you with a flexible system that adapts to your needs and your screening goals. 

Request a quote

Download Screening Solutions Resource Guide

Featured products

LentiArray CRISPR Libraries

Arrayed CRISPR libraries designed and constructed to provide a flexible system that doesn’t impose limitations on your assay design or research goals.

CRISPR Controls

High quality controls to help you optimize delivery conditions, maximize editing efficiency and establish hit selection criteria.

LentiPool CRISPR Libraries

LentiPool CRISPR libraries are an affordable method to screen a large number of genes, as there is no high-throughput instrumentation required.

LentiArray CRISPR gRNA

Predesigned, prepackaged CRISPR gRNA lentiviruses designed for efficient gene knockout.

LentiArray Cas9 Lentivirus

Cas9 Lentivirus gives you the ability to create a stable pool of Cas9-expressing cells or to isolate stable Cas9-expressing clones.

TrueGuide Synthetic gRNA

Ready-to-transfect synthetic gRNAs designed and validated to provide consistent high efficiency editing without compromising specificity.

Advance your research with award-winning solutions

LentiArray CRISPR Libraries made The Scientist’s Top 10 Innovations of 2016!

“The LentiArray CRISPR libraries have allowed us to make significant inroads in our research on pediatric cancer, discovering a potentially novel strategy for the treatment of deadly brain tumors,” said Simone Treiger Sredni M.D., Ph.D., associate professor of pediatric neurosurgery at Northwestern University Feinberg School of Medicine. “Through the use of lenti-viral CRISPR-Cas9 particles, we identified an enzyme that can be inhibited by drugs and has been shown to prohibit tumor cell growth without affecting normal cells.”

Read the complete press release